A $4.3 million to $6.3 million gap between Integra’s preliminary third-quarter revenue and the Wall Street estimate sent IART shares lower. SueWallSt notifies investors of a pending investigation into potential securities claims for shareholders who lost money.
NEW YORK, Oct. 2, 2026 /PRNewswire/ — Integra LifeSciences (NASDAQ: IART) shares fell sharply on October 2, 2026, after the Company put preliminary third-quarter revenue at $410 million to $412 million — short of the $416.3 million FactSet consensus estimate. Investors who bought IART and are now holding losses may have legal rights. Affected shareholders are encouraged to submit their IART loss details now or contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.
Integra further cut its full year revenue, “from a range of $1.654 billion to $1.695 billion to a range of $1.634 billion to $1.654 billion.” The Company blamed the shortfall on “flooding at the Cincinnati facility in July 2026,” noting the “disruption negatively impacted third quarter revenue by approximately $7 million,” and a projected further negative impact of $15 to $20 million to fourth quarter revenue. The Company further disclosed it now does not see a return to full manufacturing operations until the second quarter of 2027.
During Integra’s previous earnings call on July 29, 2026, Chief Financial Officer Lea Daniels Knight discussed the Cincinnati facility flooding incident briefly, informing investors the Company did “not expect the event to have a material impact on our revenue or EPS guidance for 2026.”
Investors who suffered losses on Integra LifeSciences shares can start a free review of their IART losses while the investigation is active, or call (888) SueWallSt.
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the IART Investigation
Q: How much did IART stock drop?A: Shares opened down $2.79 per share, or about 17% on October 2, 2026. By midday the stock had fallen further to a near 20%. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether statements Integra LifeSciences made about its manufacturing operations and projected results may have been misleading. When the Company disclosed surprise revenue impacts from a flooding event management previously characters as not expected to “have a material impact” on revenue or earnings, the stock price declined sharply.
Q: When did Integra LifeSciences allegedly mislead investors?A: The investigation concerns statements made before the October 2, 2026 disclosure that may have caused investors to purchase IART securities at inflated prices.
Q: What do IART investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my IART shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought IART and sold at a loss may still participate in the investigation.
Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/integra-lifesciences-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-integra-lifesciences-iart-302897459.html
SOURCE SueWallSt.com
